TY  - JOUR

T1  - 372 Safety and activity of the anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer

JO  - International Journal of Gynecological Cancer

UR  - https://doi.org/10.1136/ijgc-2020-igcs.322

PY  - 2020/11/01

AU  - Santin A

AU  - Vergote I

AU  - Martín A

AU  - Moore K

AU  - Oaknin A

AU  - Romero I

AU  - Diab S

AU  - Copeland LJ

AU  - Monk B

AU  - Coleman R

AU  - Herzog TJ et al

ED  - 

DO  - DOI: 10.1136/ijgc-2020-igcs.322

PB  - Elsevier BV

VL  - 30

SP  - A154

EP  - A154

Y2  - 2026/10/23

ER  -